OPR - Delayed Quote USD

TEVA Jun 2024 11.000 put (TEVA240621P00011000)

0.1900

0.0000

(0.00%)

As of April 23 at 12:26 PM EDT. Market Open.

Key Events

Loading Chart for TEVA240621P00011000

9/21 12:03 PM

DELL

Previous Close 0.1900
Open 0.1900
Bid 0.0700
Ask 0.1000
Strike 11.00
Expire Date 2024-06-21
Day's Range 0.1900 - 0.1900
Contract Range --
Volume 41
Open Interest 3.54k

UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

11 Best Low Price Pharma Stocks To Invest In

11 Best Low Price Pharma Stocks To Invest In

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

Israeli economy has proven to thrive despite crisis: Expert

Israeli economy has proven to thrive despite crisis: Expert

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

3 No-Brainer Stocks to Buy With $600 Right Now

3 No-Brainer Stocks to Buy With $600 Right Now